BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Mind the Byte

Mind the Byte logo

Founded
2011
Publications
16

Technologies

AI Companies (Drug Discovery)

Mind the Byte is a bioinformatics company that develops and provides software for computational drug discovery using Big Data and Machine Learning (AI) approaches. We work with partners on a consultancy basis or offer an easy to use Software as a Service (SaaS) package to allow clients to apply the High-performance computing platform on a flexible pay-per-use basis without investment in hardware or software licenses.

Mind the Byte has developed a versatile set of applications using cloud computing which lowers the entry barrier to the technology, e.g.

i) virtual profiling methods to facilitate the identification of targets and mechanisms of action of phenotypic screening hits or natural products with reported activity
ii) virtual screening methods to identify compounds acting on a specific target by mining internal or commercial compound libraries, to expand hit or lead series and to conduct repurposing of known drugs.
iii) MtBDock - a fully integrated docking protocol reducing the amount of false positives by incorporation of all prosthetic groups and conformational minimization
iv) SmartDock - an experimentally validated docking protocol with further improved performance based on machine learning of PDB target-ligand interactions

Mind the Byte is an Amazon Web Services technology partner - a seal of quality that has only been awarded to five companies in this sector – to ensure security and reliability. The company was founded in 2011 by Alfons Nonell-Canals, a specialist in computer-aided drug design and in large-scale chemical and biological analyses, and has since expanded with an experienced staff. The company is located at the Barcelona Science Park and Copenhagen Bio Science Park.


Posts Mentioning This Company

Artificial Intelligence For Drug Discovery Use Cases At Mind the Byte

  
UPDATE: Mind the Byte ceased operations and was liquidated in 2019. Artificial intelligence (AI) has become a hot topic in the biopharmaceutical environment and nearly every pharma company in the world has embraced it hoping that it will play a major role in speeding up drug discovery, by reducing R&D …